Secondary Outcomes Histologic Features In comparison with the placebo group, both active-treatment groupings had a significant reduction in steatosis, lobular irritation , and the activity score for nonalcoholic fatty liver disease . Although scores for hepatocellular ballooning were improved with vitamin E and with pioglitazone, only the improvement with supplement E was significant . Fibrosis scores were not considerably improved with either active treatment. Steatohepatitis resolved in a larger proportion of subjects receiving either vitamin E or pioglitazone than in those receiving placebo, but the difference was significant limited to those getting pioglitazone .Papaemmanuil, M. Cazzola, J. Boultwood, L. Malcovati, P. Vyas, D. Bowen, A. Pellagatti, J.S. Wainscoat, E. Hellstrom-Lindberg, C. Gambacorti-Passerini, A.L. Godfrey, I. Rapado, A. Cvejic, R. Rance, C. McGee, P. Ellis, L.J. Mudie, P.J. Stephens, S. McLaren, C.E. Massie, P.S. Tarpey, I. Varela, S. Nik-Zainal, H.R. Davies, A. Shlien, D. Jones, K. Raine, J. Hinton, A.P. Butler, J.W. Teague, Electronic.J. Baxter, J. Score, A. Galli, M.G. Della Porta, Electronic. Travaglino, M. Groves, S. Tauro, N.C. Munshi, K.C. Anderson, A. El-Naggar, A. Fischer, V. Mustonen, A.J. Warren, N.C.P. Cross, A.R. Green, P.A. Futreal, M.R. Stratton, and P.J. Campbell for the Chronic Myeloid Disorders Working Band of the International Cancer Genome Consortium: Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts The myelodysplastic syndromes certainly are a heterogeneous group of hematologic cancers seen as a low blood counts, most anemia commonly, and a threat of progression to acute myeloid leukemia.1 These disorders possess increased in prevalence and are expected to continue steadily to do so.10 With the exception of TET2, most of these genes are mutated in no more than 5 to 15 percent of cases, and usually the mutation rates are lower in the more benign subtypes of the disease.